{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T22:49:10Z","timestamp":1770245350798,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00393-025-01772-3","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:39:20Z","timestamp":1768405160000},"page":"26-35","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interferon-Scores im Management rheumatischer Systemerkrankungen","Interferon scores in the management of rheumatic systemic diseases"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9247-4729","authenticated-orcid":false,"given":"Claas","family":"Hinze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"F\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"1772_CR1","doi-asserted-by":"publisher","first-page":"ofad641","DOI":"10.1093\/ofid\/ofad641","volume":"11","author":"M Achleitner","year":"2024","unstructured":"Achleitner\u00a0M, Mair\u00a0NK, Danhardt\u00a0J et\u00a0al (2024) Absence of Type\u00a0I Interferon Autoantibodies or Significant Interferon Signature Alterations in Adults With Post-COVID-19 Syndrome. Open Forum Infect Dis 11:ofad641","journal-title":"Open Forum Infect Dis"},{"key":"1772_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","volume":"43","author":"PS Ang","year":"2024","unstructured":"Ang\u00a0PS, Ezenwa\u00a0E, Ko\u00a0K et\u00a0al (2024) Refractory dermatomyositis responsive to anifrolumab. JAAD Case Rep 43:27\u201329","journal-title":"JAAD Case Rep"},{"key":"1772_CR3","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1073\/pnas.1106015108","volume":"108","author":"K Arima","year":"2011","unstructured":"Arima\u00a0K, Kinoshita\u00a0A, Mishima\u00a0H et\u00a0al (2011) Proteasome assembly defect due to a\u00a0proteasome subunit beta type\u00a08 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S\u00a0A 108:14914\u201314919","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1772_CR4","doi-asserted-by":"crossref","unstructured":"Bader-Meunier B, Moreau TRJ, Aeschlimann FA et\u00a0al (2025) Myositis specific autoantibody subtypes are associated with response to Janus kinase inhibitors in patients with juvenile dermatomyositis. Rheumatol (oxford)","DOI":"10.1093\/rheumatology\/keaf214"},{"key":"1772_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler\u00a0EC, Bauer\u00a0JW, Slattery\u00a0CA et\u00a0al (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13:59\u201368","journal-title":"Mol Med"},{"key":"1772_CR6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1136\/ard-2023-225445","volume":"83","author":"T Baker","year":"2024","unstructured":"Baker\u00a0T, Sharifian\u00a0H, Newcombe\u00a0PJ et\u00a0al (2024) Type\u00a0I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a\u00a0gene expression and proteomic analysis of two phase\u00a03\u00a0trials. Ann Rheum Dis 83:1018\u20131027","journal-title":"Ann Rheum Dis"},{"key":"1772_CR7","doi-asserted-by":"crossref","unstructured":"Barrutia-Etxebarria A, De La Escribano De La Torre RM, Lopez Martinez J et\u00a0al (2025) Anifrolumab in Refractory Juvenile Dermatomyositis. Pediatr Dermatol","DOI":"10.1111\/pde.16012"},{"key":"1772_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic\u00a0Z, Maria\u00a0NI, Van Helden-Meeuwsen\u00a0CG et\u00a0al (2013) Prevalence of interferon type\u00a0I signature in CD14 monocytes of patients with Sjogren\u2019s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 72:728\u2013735","journal-title":"Ann Rheum Dis"},{"key":"1772_CR9","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","volume":"75","author":"Z Brkic","year":"2016","unstructured":"Brkic\u00a0Z, Van Bon\u00a0L, Cossu\u00a0M et\u00a0al (2016) The interferon type\u00a0I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann Rheum Dis 75:1567\u20131573","journal-title":"Ann Rheum Dis"},{"key":"1772_CR10","doi-asserted-by":"publisher","first-page":"e11792","DOI":"10.1002\/acr2.11792","volume":"7","author":"S Chaudhary","year":"2025","unstructured":"Chaudhary\u00a0S, Baumer\u00a0M, Upton\u00a0L et\u00a0al (2025) Recalcitrant Dermatomyositis Treated With Anifrolumab. ACR Open Rheumatol 7:e11792","journal-title":"ACR Open Rheumatol"},{"key":"1772_CR11","doi-asserted-by":"publisher","first-page":"648004","DOI":"10.3389\/fimmu.2021.648004","volume":"12","author":"M Contoli","year":"2021","unstructured":"Contoli\u00a0M, Papi\u00a0A, Tomassetti\u00a0L et\u00a0al (2021) Blood Interferon-alpha Levels and Severity, Outcomes, and Inflammatory Profiles in Hospitalized COVID-19\u00a0Patients. Front Immunol 12:648004","journal-title":"Front Immunol"},{"key":"1772_CR12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/annrheumdis-2022-222370","volume":"81","author":"FH Cooles","year":"2022","unstructured":"Cooles\u00a0FH, Tarn\u00a0J, Lendrem\u00a0DW et\u00a0al (2022) Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming. Ann Rheum Dis 81:1214\u20131223","journal-title":"Ann Rheum Dis"},{"key":"1772_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","volume":"14","author":"MK Crow","year":"2019","unstructured":"Crow\u00a0MK, Olferiev\u00a0M, Kirou\u00a0KA (2019) Type\u00a0I Interferons in Autoimmune Disease. Annu Rev Pathol 14:369\u2013393","journal-title":"Annu Rev Pathol"},{"key":"1772_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","volume":"1238","author":"YJ Crow","year":"2011","unstructured":"Crow\u00a0YJ (2011) Type\u00a0I interferonopathies: a\u00a0novel set of inborn errors of immunity. Ann N Y Acad Sci 1238:91\u201398","journal-title":"Ann N Y Acad Sci"},{"key":"1772_CR15","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1172\/JCI129301","volume":"130","author":"AA De Jesus","year":"2020","unstructured":"De Jesus\u00a0AA, Hou\u00a0Y, Brooks\u00a0S et\u00a0al (2020) Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J\u00a0Clin Invest 130:1669\u20131682","journal-title":"J Clin Invest"},{"key":"1772_CR16","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","volume":"14","author":"W Feng","year":"2023","unstructured":"Feng\u00a0W, Beer\u00a0JC, Hao\u00a0Q et\u00a0al (2023) NULISA: a\u00a0proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun 14:7238","journal-title":"Nat Commun"},{"key":"1772_CR17","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1002\/art.22044","volume":"54","author":"X Feng","year":"2006","unstructured":"Feng\u00a0X, Wu\u00a0H, Grossman\u00a0JM et\u00a0al (2006) Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 54:2951\u20132962","journal-title":"Arthritis Rheum"},{"key":"1772_CR18","doi-asserted-by":"crossref","unstructured":"Fremond ML, David C, Richez C (2024) Anifrolumab: the new frontier in the treatment of genetic interferonopathies. RMD Open 10:","DOI":"10.1136\/rmdopen-2024-004780"},{"key":"1772_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie\u00a0R, Khamashta\u00a0M, Merrill\u00a0JT et\u00a0al (2017) Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol 69:376\u2013386","journal-title":"Arthritis Rheumatol"},{"key":"1772_CR20","doi-asserted-by":"crossref","unstructured":"Graf M, Von Stuckrad SL, Uruha A et\u00a0al (2022) SIGLEC1 enables straightforward assessment of type\u00a0I interferon activity in idiopathic inflammatory myopathies. RMD Open 8:","DOI":"10.1136\/rmdopen-2021-001934"},{"key":"1772_CR21","doi-asserted-by":"publisher","first-page":"1253279","DOI":"10.3389\/fimmu.2023.1253279","volume":"14","author":"C Gunther","year":"2023","unstructured":"Gunther\u00a0C, Wolf\u00a0C, Fennen\u00a0L et\u00a0al (2023) Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood. Front Immunol 14:1253279","journal-title":"Front Immunol"},{"key":"1772_CR22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj\u00a0J, Yatim\u00a0N, Barnabei\u00a0L et\u00a0al (2020) Impaired type\u00a0I interferon activity and inflammatory responses in severe COVID-19\u00a0patients. Science 369:718\u2013724","journal-title":"Science"},{"key":"1772_CR23","doi-asserted-by":"crossref","unstructured":"Huang Z, Brodeur KE, Chen L et\u00a0al (2023) Type\u00a0I interferon signature and cycling lymphocytes in macrophage activation syndrome. J\u00a0Clin Invest 133:","DOI":"10.1172\/JCI165616"},{"key":"1772_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","volume":"34","author":"V Kakkar","year":"2022","unstructured":"Kakkar\u00a0V, Assassi\u00a0S, Allanore\u00a0Y et\u00a0al (2022) Type\u00a01 interferon activation in systemic sclerosis: a\u00a0biomarker, a\u00a0target or the culprit. Curr Opin Rheumatol 34:357\u2013364","journal-title":"Curr Opin Rheumatol"},{"key":"1772_CR25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/art.41790","volume":"73","author":"T Kato","year":"2021","unstructured":"Kato\u00a0T, Yamamoto\u00a0M, Honda\u00a0Y et\u00a0al (2021) Augmentation of Stimulator of Interferon Genes-Induced Type\u00a0I Interferon Production in COPA Syndrome. Arthritis Rheumatol 73:2105\u20132115","journal-title":"Arthritis Rheumatol"},{"key":"1772_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/1744666X.2024.2312819","volume":"20","author":"H Kim","year":"2024","unstructured":"Kim\u00a0H (2024) Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis. Expert Rev Clin Immunol 20:589\u2013602","journal-title":"Expert Rev Clin Immunol"},{"key":"1772_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/jir.2017.0127","volume":"38","author":"H Kim","year":"2018","unstructured":"Kim\u00a0H, De Jesus\u00a0AA, Brooks\u00a0SR et\u00a0al (2018) Development of a\u00a0Validated Interferon Score Using NanoString Technology. J\u00a0Interferon Cytokine Res 38:171\u2013185","journal-title":"J Interferon Cytokine Res"},{"key":"1772_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13075-023-02997-w","volume":"25","author":"ST Kim","year":"2023","unstructured":"Kim\u00a0ST, Munoz-Grajales\u00a0C, Dunn\u00a0SE et\u00a0al (2023) Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA(+) individuals without a\u00a0systemic autoimmune rheumatic disease diagnosis. Arthritis Res Ther 25:21","journal-title":"Arthritis Res Ther"},{"key":"1772_CR29","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","volume":"61","author":"B Lerkvaleekul","year":"2022","unstructured":"Lerkvaleekul\u00a0B, Veldkamp\u00a0SR, Van Der Wal\u00a0MM et\u00a0al (2022) Siglec\u20111 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatol (oxford) 61:2144\u20132155","journal-title":"Rheumatol (oxford)"},{"key":"1772_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu\u00a0Y, Jesus\u00a0AA, Marrero\u00a0B et\u00a0al (2014) Activated STING in a\u00a0vascular and pulmonary syndrome. N\u00a0Engl J Med 371:507\u2013518","journal-title":"N Engl J Med"},{"key":"1772_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","volume":"64","author":"Y Liu","year":"2012","unstructured":"Liu\u00a0Y, Ramot\u00a0Y, Torrelo\u00a0A et\u00a0al (2012) Mutations in proteasome subunit beta type\u00a08 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64:895\u2013907","journal-title":"Arthritis Rheum"},{"key":"1772_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13075-021-02414-0","volume":"23","author":"L Mai","year":"2021","unstructured":"Mai\u00a0L, Asaduzzaman\u00a0A, Noamani\u00a0B et\u00a0al (2021) The baseline interferon signature predicts disease severity over the subsequent 5\u00a0years in systemic lupus erythematosus. Arthritis Res Ther 23:29","journal-title":"Arthritis Res Ther"},{"key":"1772_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F Mcnab","year":"2015","unstructured":"Mcnab\u00a0F, Mayer-Barber\u00a0K, Sher\u00a0A et\u00a0al (2015) Type\u00a0I interferons in infectious disease. Nat Rev Immunol 15:87\u2013103","journal-title":"Nat Rev Immunol"},{"key":"1772_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N\u00a0Engl J Med 382:211\u2013221","journal-title":"N Engl J Med"},{"key":"1772_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","volume":"14","author":"TLW Muskardin","year":"2018","unstructured":"Muskardin\u00a0TLW, Niewold\u00a0TB (2018) Type\u00a0I interferon in rheumatic diseases. Nat Rev Rheumatol 14:214\u2013228","journal-title":"Nat Rev Rheumatol"},{"key":"1772_CR36","doi-asserted-by":"crossref","unstructured":"Nocturne G, Mariette X (2022) Interferon signature in systemic autoimmune diseases: what does it mean? RMD Open 8:","DOI":"10.1136\/rmdopen-2022-002687"},{"key":"1772_CR37","doi-asserted-by":"crossref","unstructured":"Nombel A, Foray AP, Garnier L et\u00a0al (2023) Assessment of type\u00a0I interferon response in routine practice in France in 2022. RMD Open 9:","DOI":"10.1136\/rmdopen-2023-003211"},{"key":"1772_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.40810","volume":"71","author":"D Plant","year":"2019","unstructured":"Plant\u00a0D, Maciejewski\u00a0M, Smith\u00a0S et\u00a0al (2019) Profiling of Gene Expression Biomarkers as a\u00a0Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. Arthritis Rheumatol 71:678\u2013684","journal-title":"Arthritis Rheumatol"},{"key":"1772_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias\u00a0LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375\u2013386","journal-title":"Nat Rev Immunol"},{"key":"1772_CR40","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/03009742.2025.2503573","volume":"54","author":"SJ Rahbek","year":"2025","unstructured":"Rahbek\u00a0SJ, Tandrup Nielsen\u00a0C, Lindhardsen\u00a0J et\u00a0al (2025) Anifrolumab for refractory dermatomyositis: a\u00a0case series. Scand J Rheumatol 54:387\u2013389","journal-title":"Scand J Rheumatol"},{"key":"1772_CR41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1086\/521373","volume":"81","author":"G Rice","year":"2007","unstructured":"Rice\u00a0G, Patrick\u00a0T, Parmar\u00a0R et\u00a0al (2007) Clinical and molecular phenotype of Aicardi-Goutieres syndrome. Am J Hum Genet 81:713\u2013725","journal-title":"Am J Hum Genet"},{"key":"1772_CR42","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ng.373","volume":"41","author":"GI Rice","year":"2009","unstructured":"Rice\u00a0GI, Bond\u00a0J, Asipu\u00a0A et\u00a0al (2009) Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 41:829\u2013832","journal-title":"Nat Genet"},{"key":"1772_CR43","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","volume":"12","author":"GI Rice","year":"2013","unstructured":"Rice\u00a0GI, Forte\u00a0GM, Szynkiewicz\u00a0M et\u00a0al (2013) Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a\u00a0case-control study. Lancet Neurol 12:1159\u20131169","journal-title":"Lancet Neurol"},{"key":"1772_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","volume":"37","author":"GI Rice","year":"2017","unstructured":"Rice\u00a0GI, Melki\u00a0I, Fremond\u00a0ML et\u00a0al (2017) Assessment of Type\u00a0I Interferon Signaling in Pediatric Inflammatory Disease. J\u00a0Clin Immunol 37:123\u2013132","journal-title":"J Clin Immunol"},{"key":"1772_CR45","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1084\/jem.20161596","volume":"213","author":"MP Rodero","year":"2016","unstructured":"Rodero\u00a0MP, Crow\u00a0YJ (2016) Type\u00a0I interferon-mediated monogenic autoinflammation: The type\u00a0I interferonopathies, a\u00a0conceptual overview. J\u00a0Exp Med 213:2527\u20132538","journal-title":"J Exp Med"},{"key":"1772_CR46","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1084\/jem.20161451","volume":"214","author":"MP Rodero","year":"2017","unstructured":"Rodero\u00a0MP, Decalf\u00a0J, Bondet\u00a0V et\u00a0al (2017) Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J\u00a0Exp Med 214:1547\u20131555","journal-title":"J Exp Med"},{"key":"1772_CR47","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard-2022-223628","volume":"82","author":"J Rodriguez-Carrio","year":"2023","unstructured":"Rodriguez-Carrio\u00a0J, Burska\u00a0A, Conaghan\u00a0PG et\u00a0al (2023) 2022 EULAR points to consider for the measurement, reporting and application of IFN\u2011I pathway activation assays in clinical research and practice. Ann Rheum Dis 82:754\u2013762","journal-title":"Ann Rheum Dis"},{"key":"1772_CR48","doi-asserted-by":"publisher","first-page":"e000270","DOI":"10.1136\/lupus-2018-000270","volume":"6","author":"L Ronnblom","year":"2019","unstructured":"Ronnblom\u00a0L, Leonard\u00a0D (2019) Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 6:e270","journal-title":"Lupus Sci Med"},{"key":"1772_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","volume":"160","author":"KS Shaw","year":"2024","unstructured":"Shaw\u00a0KS, Reusch\u00a0DB, Castillo\u00a0RL et\u00a0al (2024) Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment. JAMA Dermatol 160:237\u2013238","journal-title":"JAMA Dermatol"},{"key":"1772_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4049\/jimmunol.1501061","volume":"196","author":"M Sjostrand","year":"2016","unstructured":"Sjostrand\u00a0M, Johansson\u00a0A, Aqrawi\u00a0L et\u00a0al (2016) The Expression of BAFF Is Controlled by IRF Transcription Factors. J\u00a0Immunol 196:91\u201396","journal-title":"J Immunol"},{"key":"1772_CR51","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.ard.2025.02.002","volume":"84","author":"C Triaille","year":"2025","unstructured":"Triaille\u00a0C, Piram\u00a0M, Ellezam\u00a0B et\u00a0al (2025) Rapid clinical and transcriptomic response to anifrolumab in refractory anti-TIF1gamma-positive juvenile dermatomyositis. Ann Rheum Dis 84:1052\u20131054","journal-title":"Ann Rheum Dis"},{"key":"1772_CR52","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1002\/art.42265","volume":"74","author":"D Trutschel","year":"2022","unstructured":"Trutschel\u00a0D, Bost\u00a0P, Mariette\u00a0X et\u00a0al (2022) Variability of Primary Sjogren\u2019s Syndrome Is Driven by Interferon-alpha and Interferon-alpha Blood Levels Are Associated With the Class\u00a0II HLA-DQ Locus. Arthritis Rheumatol 74:1991\u20132002","journal-title":"Arthritis Rheumatol"},{"key":"1772_CR53","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver\u00a0A, Adang\u00a0L, Gavazzi\u00a0F et\u00a0al (2020) Janus Kinase Inhibition in the Aicardi-Goutieres Syndrome. N\u00a0Engl J Med 383:986\u2013989","journal-title":"N Engl J Med"},{"key":"1772_CR54","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","volume":"81","author":"EM Vital","year":"2022","unstructured":"Vital\u00a0EM, Merrill\u00a0JT, Morand\u00a0EF et\u00a0al (2022) Anifrolumab efficacy and safety by type\u00a0I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase\u00a0III trials. Ann Rheum Dis 81:951\u2013961","journal-title":"Ann Rheum Dis"},{"key":"1772_CR55","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1080\/14656566.2024.2392021","volume":"25","author":"RS Wallwork","year":"2024","unstructured":"Wallwork\u00a0RS, Paik\u00a0JJ, Kim\u00a0H (2024) Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons. Expert Opin Pharmacother 25:1625\u20131645","journal-title":"Expert Opin Pharmacother"},{"key":"1772_CR56","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/acr2.11618","volume":"5","author":"C Weiden","year":"2023","unstructured":"Weiden\u00a0C, Saers\u00a0M, Schwarz\u00a0T et\u00a0al (2023) Type\u00a01 Interferon-Stimulated Gene Expression and Disease Activity in Pediatric Rheumatic Diseases: No Composite Scores Needed? ACR Open Rheumatol 5:652\u2013662","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"1772_CR57","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1186\/ar2887","volume":"12","author":"Y Yao","year":"2010","unstructured":"Yao\u00a0Y, Higgs\u00a0BW, Richman\u00a0L et\u00a0al (2010) Use of type\u00a0I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNalpha antibody, in systemic lupus erythematosus. Arthritis Res Ther 12(1):S6","journal-title":"Arthritis Res Ther"},{"key":"1772_CR58","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/art.22382","volume":"56","author":"MR York","year":"2007","unstructured":"York\u00a0MR, Nagai\u00a0T, Mangini\u00a0AJ et\u00a0al (2007) A macrophage marker, Siglec\u20111, is increased on circulating monocytes in patients with systemic sclerosis and induced by type\u00a0I interferons and toll-like receptor agonists. Arthritis Rheum 56:1010\u20131020","journal-title":"Arthritis Rheum"},{"key":"1772_CR59","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/jamadermatol.2018.5077","volume":"155","author":"N Zimmermann","year":"2019","unstructured":"Zimmermann\u00a0N, Wolf\u00a0C, Schwenke\u00a0R et\u00a0al (2019) Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation. JAMA Dermatol 155:342\u2013346","journal-title":"JAMA Dermatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01772-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01772-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:02:50Z","timestamp":1770199370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01772-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1772"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01772-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Hinze und D.\u00a0F\u00f6ll geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}